🔎 Trials Near Me

Beranda › Kanker Kepala dan Leher › Tennessee › Nashville

Uji klinis Kanker Kepala dan Leher di Nashville, TN

21 studi untuk Kanker Kepala dan Leher mencari peserta di lokasi sekitar Nashville (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Menerima pesertaFase 1/2
  • Sarah Cannon Research Institute, Nashville
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04585750

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Menerima pesertaFase 2/3
  • Site#0126, Nashville
  • Site #0116, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06788990

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Menerima pesertaFase 2
  • SCRI Oncology Partners, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06172478

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Menerima pesertaFase 1
  • Sarah Cannon Research Institute - Pharmacy, Nashville
  • SCRI Oncology Partners, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07090499

DESTINY-PANTUMOUR04

Menerima pesertaStudi observasional
  • Research Site, Nashville
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07124000

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

Menerima pesertaFase 1
  • Sarah Cannon and HCA Research Institute, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT07462377

Self-Management for Head and Neck Lymphedema and Fibrosis [PROMISE Trial]

Menerima peserta
  • Barbara Murphy, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT06125743

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Menerima pesertaFase 1/2
  • Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT05592626

Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer

Menerima pesertaFase 1
  • Vanderbilt University Medical Center, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT06819228

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Menerima pesertaFase 1/2
  • Sarah Cannon Research Institute, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Jul 2026 · NCT05768139

Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

Menerima pesertaFase 1
  • Vanderbilt University Medical Center, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Jul 2026 · NCT07460765

Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema

Menerima peserta
  • Vanderbilt University Medical Center, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Jun 2026 · NCT06837480

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Menerima pesertaFase 3
  • GSK Investigational Site, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Mei 2026 · NCT06256588

High-Resolution PET-CT Imaging for Surgical Margin Visualization

Menerima peserta
  • Vanderbilt University Medical Center, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Mei 2026 · NCT06915454

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Menerima pesertaFase 1/2
  • Sarah Cannon Research Institute, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT06239194

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

Menerima pesertaStudi observasionalSukarelawan sehat diterima
  • Vanderbilt-Ingram Cancer Center, Nashville
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 20 Jan 2026 · NCT05366881

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Menerima pesertaStudi observasional
  • Massive Bio SYNERGY-AI site, Nashville
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774

Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants

Menerima pesertaStudi observasionalSukarelawan sehat diterima
  • Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville
  • Vanderbilt-Ingram Cancer Center at Franklin, Nashville
  • Veterans Affairs Medical Center - Nashville, Nashville
  • dan 1 lainnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT00898638

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Menerima pesertaFase 1/2
  • Tennessee Oncology, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2025 · NCT05941507

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Menerima pesertaFase 1
  • Vanderbilt University Medical Center, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Agu 2025 · NCT04429542

Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer

Menerima pesertaFase 1/2
  • Vanderbilt-Ingram Cancer Center, Nashville
Usia 21 ke atas · Semua jenis kelamin · Diperbarui 21 Okt 2024 · NCT05156060

Uji klinis Kanker Kepala dan Leher di kota lain

Studi lain di Nashville

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.